Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Webcasts


Play A background to siRNA: Pushkal Garg, Alnylam
Pushkal Garg A background to siRNA: Pushkal Garg, Alnylam
Play How do we identify very high risk patients for PCSK9 inhibition? Part Two
Ulf Landmesser How do we identify very high risk patients for PCSK9 inhibition? Part Two
Play How do we identify very high risk patients for PCSK9 inhibition? Part One
Erik Stroes How do we identify very high risk patients for PCSK9 inhibition? Part One
Play Profiling patients with ACS: What are the prospects for PCSK9 inhibition?
Gregory G. Schwartz Profiling patients with ACS: What are the prospects for PCSK9 inhibition?
Play PCSK9 and the beta-cell
Bertrand Cariou PCSK9 and the beta-cell
Play Intracellular actions of PCSK9
Jan Albert Kuivenhoven Intracellular actions of PCSK9
Play Back to basics on cost-effectiveness
Anthony Wierzbicki Back to basics on cost-effectiveness
Play Where are we with CVD prevention guidelines?
Henry Ginsberg Where are we with CVD prevention guidelines?
Play Preventing cardiovascular disease: the value of early signs of cardiac injury
Chris Packard Preventing cardiovascular disease: the value of early signs of cardiac injury
Play What can we learn from Mendelian randomisation about the impact of lipid lowering on CVD and risk of dysglycaemia?
Brian Ference What can we learn from Mendelian randomisation about the impact of lipid lowering on CVD and risk of dysglycaemia?
Play Insights from Chile: Rodrigo Alonso, Clínica Las Condes, Santiago de Chile
Rodrigo Alonso Insights from Chile: Rodrigo Alonso, Clínica Las Condes, Santiago de Chile
Play Insights from Brazil: Raul Santos, InCor-University of Sao Paulo
Raul Santos Insights from Brazil: Raul Santos, InCor-University of Sao Paulo
Play Outcomes data are critical
Francois Mach Outcomes data are critical
Play Collaboration between patient associations and healthcare professionals is key
Gunnar Karlsson Collaboration between patient associations and healthcare professionals is key
Play Many key barriers are amenable to change; new strategies are needed
David Hare Many key barriers are amenable to change; new strategies are needed
Play What prevents high risk patients gaining access to treatment with PCSK9 inhibitors?
What prevents high risk patients gaining access to treatment with PCSK9 inhibitors?
Play PCSK9 inhibitors: Who and when to treat?
Anthony Wierzbicki PCSK9 inhibitors: Who and when to treat?
Play Current status of IVUS studies of plaque burden: what next with GLAGOV?
Steve Nicholls Current status of IVUS studies of plaque burden: what next with GLAGOV?
Play PCSK9 inhibition at the limits
John Chapman PCSK9 inhibition at the limits
Play How does PCSK9 inhibition influence cholesterol metabolism in humans?
Bo Angelin How does PCSK9 inhibition influence cholesterol metabolism in humans?

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
Educational Partners and Supporters
AstraZeneca AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation
Lib Therapeutics Novartis Sanofi
© Copyright 2024 PCSK9 Forum. All rights reserved